Is Serum Magnesium Level Associated With Serum Lipid Levels in Kidney Transplant Recipients?


Journal

Transplantation proceedings
ISSN: 1873-2623
Titre abrégé: Transplant Proc
Pays: United States
ID NLM: 0243532

Informations de publication

Date de publication:
Jun 2023
Historique:
received: 29 10 2022
accepted: 05 01 2023
medline: 3 7 2023
pubmed: 13 4 2023
entrez: 12 4 2023
Statut: ppublish

Résumé

Magnesium (Mg) is key in diabetes mellitus, hyperlipidemia, and cardiovascular disease. This is a retrospective cross-sectional study including 103 kidney transplant recipients. Patients aged under 18 years, patients treated with Mg supplementation, antihyperlipidemic agents, or diuretics, and patients with active infection or malignancy were not enrolled. Patients were divided into 2 groups according to median serum Mg level. The atherogenic index of plasma was calculated by a logarithmic transformation of the number acquired by dividing the molar concentrations of serum triglyceride by high-density lipoprotein value. The mean serum Mg level was 1.91 ± 0.28 mg/dL. Six patients (5.8%) had hypomagnesemia (Mg <1.5 mg/dL), and 2 (1.9%) had hypermagnesemia (Mg >2.6 mg/dL). Serum Mg level was negatively correlated with body mass index, estimated glomerular filtration rate (eGFR), and tacrolimus trough level and positively correlated with levels of phosphorus, total cholesterol, and low-density lipoprotein (LDL-C). There was no correlation between serum Mg and triglyceride, high-density lipoprotein, atherogenic index of plasma, and cyclosporin A trough level. Patients with Mg >1.87 mg/dL had lower eGFR, tacrolimus, and cyclosporin A trough level and higher total cholesterol and LDL-C compared to those with Mg ≤1.87 mg/dL. In adjusted ordinal analysis, eGFR (hazard ratio (HR): 0.981, 95% CI 0.964-0.999, P = .036) and total cholesterol (HR: 1.015, 95% CI 1.004-1.027, P = .008) were independently associated with serum Mg. In multivariate linear regression analysis, serum Mg level was independently associated with LDL-C (β = .296, t = 3.079, P = .003) and total cholesterol (β = .295, t = 3.075, P = .003). Serum Mg level may have an important impact on dyslipidemia in kidney transplant recipients.

Sections du résumé

BACKGROUND BACKGROUND
Magnesium (Mg) is key in diabetes mellitus, hyperlipidemia, and cardiovascular disease.
METHODS METHODS
This is a retrospective cross-sectional study including 103 kidney transplant recipients. Patients aged under 18 years, patients treated with Mg supplementation, antihyperlipidemic agents, or diuretics, and patients with active infection or malignancy were not enrolled. Patients were divided into 2 groups according to median serum Mg level. The atherogenic index of plasma was calculated by a logarithmic transformation of the number acquired by dividing the molar concentrations of serum triglyceride by high-density lipoprotein value.
RESULTS RESULTS
The mean serum Mg level was 1.91 ± 0.28 mg/dL. Six patients (5.8%) had hypomagnesemia (Mg <1.5 mg/dL), and 2 (1.9%) had hypermagnesemia (Mg >2.6 mg/dL). Serum Mg level was negatively correlated with body mass index, estimated glomerular filtration rate (eGFR), and tacrolimus trough level and positively correlated with levels of phosphorus, total cholesterol, and low-density lipoprotein (LDL-C). There was no correlation between serum Mg and triglyceride, high-density lipoprotein, atherogenic index of plasma, and cyclosporin A trough level. Patients with Mg >1.87 mg/dL had lower eGFR, tacrolimus, and cyclosporin A trough level and higher total cholesterol and LDL-C compared to those with Mg ≤1.87 mg/dL. In adjusted ordinal analysis, eGFR (hazard ratio (HR): 0.981, 95% CI 0.964-0.999, P = .036) and total cholesterol (HR: 1.015, 95% CI 1.004-1.027, P = .008) were independently associated with serum Mg. In multivariate linear regression analysis, serum Mg level was independently associated with LDL-C (β = .296, t = 3.079, P = .003) and total cholesterol (β = .295, t = 3.075, P = .003).
CONCLUSION CONCLUSIONS
Serum Mg level may have an important impact on dyslipidemia in kidney transplant recipients.

Identifiants

pubmed: 37045703
pii: S0041-1345(23)00161-6
doi: 10.1016/j.transproceed.2023.01.041
pii:
doi:

Substances chimiques

Tacrolimus WM0HAQ4WNM
Cyclosporine 83HN0GTJ6D
Magnesium I38ZP9992A
Cholesterol, LDL 0
Triglycerides 0
Lipoproteins, HDL 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1147-1151

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Auteurs

Berk Goktepe (B)

Ege University, School of Medicine, Department of General Surgery, Bornova, Izmir, Turkey.

Aygul Celtik (A)

Ege University, School of Medicine, Department of Internal Medicine, Division of Nephrology, Bornova, Izmir, Turkey. Electronic address: aygul.celtik@ege.edu.tr.

Goktug Kivratma (G)

Ege University, School of Medicine, Department of General Surgery, Bornova, Izmir, Turkey.

Taylan Ozgur Sezer (TO)

Ege University, School of Medicine, Department of General Surgery, Bornova, Izmir, Turkey.

Gulay Asci (G)

Ege University, School of Medicine, Department of Internal Medicine, Division of Nephrology, Bornova, Izmir, Turkey.

Huseyin Toz (H)

Ege University, School of Medicine, Department of Internal Medicine, Division of Nephrology, Bornova, Izmir, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH